Emma Parkinson-Lawrence

Dr Emma Parkinson-Lawrence

Program Director: Medical Sciences

School of Pharmacy and Biomedical Science

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Available For Media Comment.


Having been trained as a Biochemist and establishing a strong desire to work in the area of protein dysfunction and disease pathogenesis I was fortunate to obtain a research position in the Lysosomal Diseases Research Unit at the Women’s in Children’s Hospital. I became involved in research to understand the molecular mechanisms of lysosomal disease pathogenesis and developed diagnostic assays. During this time, I became particularly interested in the neurological dysfunction associated with these diseases, in particular Sanfilippo Syndrome, and commenced a research program looking at the role of altered neurotransmission and disease progression, having been awarded an NHMRC Peter Doherty Early Career Research Fellowship. At the completion of my fellowship I obtained a research-teaching academic position at the University of South Australia.
Serendipity and discussions with Professor Sandra Orgeig have evoked a new research program investigating the molecular mechanisms that may impact respiratory dysfunction in Sanfilippo Syndrome but may also contribute to other lysosomal diseases; underlying molecular mechanisms contributing to both neurological and respiratory dysfunction. This includes a continuing collaboration with Associate Kim Hemsley (Flinders University) and co supervision of PhD students. During my research career thus far, I have had the privilege to attend and present our research findings at several international MPS and related disease conferences and interacted with many amazing patients and their families, clinicians and scientists. This truly reinforces to me why I continue to do what I do.
As a senior scientist in the Mechanisms in Cell Biology and Disease research group I am also been involved in projects focussed on the endosome-lysosome system and cancer pathogenesis.

Movement/traffic of proteins and organelles within the intracellular environment; particularly neurons,Protein structure and function

Year Citation
2025 Ngai, Y. T., Young, C., Parkinson-Lawrence, E. J., Wimmer-Kleikamp, S., Mittal, P., Beard, H., . . . Hoffmann, P. (2025). Defining lung pathogenesis in a murine model of mucopolysaccharidosis Type I by proteomic analysis. Molecular Genetics and Metabolism, 146(1-2), 109231.
DOI
2024 Paget, T. L., Larcombe, A. N., Pinniger, G. J., Tsioutsias, I., Schneider, J. P., Parkinson-Lawrence, E. J., & Orgeig, S. (2024). Mucopolysaccharidosis (MPS IIIA) mice have increased lung compliance and airway resistance, decreased diaphragm strength, and no change in alveolar structure. American Journal of Physiology Lung Cellular and Molecular Physiology, 326(6), L713-L726.
DOI Scopus2 WoS2 Europe PMC1
2024 Ngai, Y. T., Briggs, M. T., Mittal, P., Young, C., Parkinson-Lawrence, E., Klingler-Hoffmann, M., . . . Hoffmann, P. (2024). Mass spectrometry imaging protocol for spatial mapping of lipids, N-glycans and peptides in murine lung tissue. Rapid Communications in Mass Spectrometry, 38(9), e9721.
DOI Scopus6 WoS4 Europe PMC3
2024 Beard, H., Winner, L., Shoubridge, A., Parkinson-Lawrence, E., Lau, A. A., Mubarokah, S. N., . . . Hemsley, K. M. (2024). Evaluation of neuroretina following i.v. or intra-CSF AAV9 gene replacement in mice with MPS IIIA, a childhood dementia. CNS Neurosci Ther, 30(8), e14919-1-e14919-13.
DOI
2024 Nturubika, B. D. D., Logan, J., Johnson, I. R. D., Moore, C., Li, K. L., Tang, J., . . . Brooks, D. A. (2024). Components of the endosome-lysosome vesicular machinery as drivers of the metastatic cascade in prostate cancer. Cancers, 17(1), 1, article no. 43-31.
DOI Scopus2 WoS2 Europe PMC1
2023 Martini, C., Logan, J. M., Sorvina, A., Gordon, C., Beck, A. R., S-Y Ung, B., . . . Brooks, D. A. (2023). Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer. Pathology, 55(1), 40-51.
DOI Scopus19 WoS18 Europe PMC18
2022 Ruvini L Dabare, P., Bachhuka, A., Palms, D., Parkinson-Lawrence, E., Hayball, J. D., Mierczynska, A., & Vasilev, K. (2022). Surface chemistry mediated albumin adsorption, conformational changes and influence on innate immune responses. Applied Surface Science, 596(article no. 153518), 11 pages.
DOI Scopus22 WoS20
2021 Paget, T. L., Parkinson-Lawrence, E. J., Trim, P. J., Autilio, C., Panchal, M. H., Koster, G., . . . Orgeig, S. (2021). Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse.. Cells, 10(4), 849.
DOI Scopus8 WoS7 Europe PMC5
2021 Lazniewska, J., Agostino, M., Hickey, S. M., Parkinson Lawrence, E., Stagni, S., Massi, M., . . . Plush, S. E. (2021). Spectroscopic and molecular docking study of the interaction between neutral Re(I) tetrazolate complexes and bovine serum albumin. Chemistry: A European Journal, Online(44), 1-22.
DOI Scopus14 WoS12 Europe PMC8
2021 Dabare, P. R. L., Bachhuka, A., Parkinson-Lawrence, E., & Vasilev, K. (2021). Surface nanotopography mediated albumin adsorption, unfolding and modulation of early innate immune responses. Materials Today Advances, 12(article no. 100187), 100187-1-100187-13.
DOI Scopus20 WoS20
2021 Paget, T. L., Parkinson Lawrence, E. J., & Orgeig, S. (2021). The role of surfactant and distal lung dysfunction in the pathology of lysosomal storage diseases. Current Opinion in Physiology, 23(article no. 100467), 1-8.
DOI Scopus2 WoS1
2020 Sorvina, A., Shandala, T., Wang, S., Sharkey, D. J., Parkinson-Lawrence, E., Selemidis, S., & Brooks, D. A. (2020). CDKI-73 is a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion. Cells, 9(2), 1-17.
DOI Scopus9 WoS8 Europe PMC8
2019 Yazbeck, R., Jaenisch, S., Squire, M., Abbott, C. A., Parkinson Lawrence, E., Brooks, D. A., & Butler, R. N. (2019). Development of a ¹³C stable isotope assay for dipeptidyl peptidase-4 enzyme activity a new breath test for dipeptidyl peptidase activity. Scientific reports, 9(article no. 4906), 1-9.
DOI Scopus4 WoS3 Europe PMC2
2019 Paget, T. L., Parkinson Lawrence, E. J., & Orgeig, S. (2019). Interstitial lung disease and surfactant dysfunction as a secondary manifestation of disease: insights from lysosomal storage disorders. Drug discovery today: disease models, 29, 35-42.
DOI Scopus8
2019 Johnson, I. R. D., Sorvina, A., Logan, J. M., Moore, C. R., Heatlie, J. K., Parkinson-Lawrence, E. J., . . . Brooks, D. A. (2019). A paradigm in immunochemistry, revealed by monoclonal antibodies to spatially distinct epitopes on Syntenin-1. International Journal of Molecular Sciences, 20(23), 6035-1-6035-16.
DOI Scopus7 WoS7 Europe PMC5
2019 Visalakshan, R. M., Cavallaro, A. A., MacGregor, M. N., Lawrence, E. P., Koynov, K., Hayball, J. D., & Vasilev, K. (2019). Nanotopography-induced unfolding of fibrinogen modulates leukocyte binding and activation. Advanced Functional Materials, 29(14), 1807453-1-1807453-12.
DOI Scopus43 WoS44
2018 Sorvina, A., Bader, C. A., Caporale, C., Carter, E. A., Johnson, I. R. D., Parkinson Lawrence, E. J., . . . Plush, S. E. (2018). Lipid profiles of prostate cancer cells. Oncotarget, 9(85), 35541-35552.
DOI Scopus39 Europe PMC25
2018 Orgeig, S., Autilio, C., Echaide, M., Paget, T., Perez Gil, J., & Parkinson Lawrence, E. (2018). Pulmonary surfactant activity is reduced in mucopolysaccharidosis type IIIa mice. Respirology, 23(S1), 116.
2018 Orgeig, S., Paget, T., Panchal, M., Postle, A., & Parkinson Lawrence, E. (2018). Alveolar surfactant phospholipid content is reduced in mucopolysaccharidosis type IIA lungs. Respirology, 23(S1), 183.
2017 Beard, H., Hassiotis, S., Gai, W. -P., Parkinson-Lawrence, E., Hopwood, J. J., & Hemsley, K. M. (2017). Axonal dystrophy in the brain of mice with Sanfilippo syndrome. Experimental Neurology, 295, 243-255.
DOI Scopus36 WoS34 Europe PMC37
2015 Johnson, I., Parkinson-Lawrence, E., Keegan, H., Spillane, C., Barry-O'Crowley, J., Watson, W., . . . Brooks, D. (2015). Endosomal gene expression: a new indicator for prostate cancer patient prognosis?. Oncotarget, 6(35), 37919-37929.
DOI Scopus40 WoS37 Europe PMC38
2014 Johnson, I., Parkinson-Lawrence, E., Shandala, T., Weigert, R., Butler, L., & Brooks, D. (2014). Altered endosome biogenesis in prostate cancer has biomarker potential. Molecular Cancer Research, 12(12), 1851-1862.
DOI Scopus44 WoS43 Europe PMC38
2014 Johnson, I., Parkinson-Lawrence, E., Butler, L., & Brooks, D. (2014). Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers. Prostate, 74(5), 547-560.
DOI Scopus22 WoS20 Europe PMC17
2012 Keating, D., Winter, M., Hemsley, K., Mackenzie, K., Teo, E., Hopwood, J., . . . Parkinson-Lawrence, E. (2012). Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells. Neuroscience, 227(27), 110-118.
DOI Scopus17 WoS17 Europe PMC12
2012 Yazbeck, R., Dawson, P., Rogers, N., West, C., Keogh, R., Wallace, D., . . . Parkinson-Lawrence, E. (2012). Indigenous health: ACTION on Prevention - 50th annual Australian society for medical research national scientific conference. Rural and Remote Health, 12(3), 5 pages.
DOI
2012 Ponder, K., O'Malley, T., Wang, P., O'Donnell, P., Traas, A., Knox, V., . . . Haskins, M. (2012). Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats. Molecular Therapy, 20(5), 898-907.
DOI Scopus20 WoS20 Europe PMC17
2012 Yazbeck, R., Dawson, P., Rogers, N., West, C., Keogh, R., Wallace, D., . . . Parkinson Lawrence, E. (2012). Indigenous health: action on prevention - 50th annual Australian society for medical research national scientific conference. Rural and remote health, 12(3), 1-5.
2010 Parkinson-Lawrence, E., Shandala, T., Prodoehl, M., Plew, R., Borlace, G., & Brooks, D. (2010). Lysosomal storage disease : revealing lysosomal function and physiology. Physiology, 25(2), 102-115.
DOI Scopus200 WoS184 Europe PMC145
2007 Shoubridge, C., Cloosterman, D., Parkinson-Lawrence, E., Brooks, D., & Gecz, J. (2007). Molecular pathology of expanded polyalanine tract mutations in the Aristaless-related homeobox gene. Genomics, 90(1), 59-71.
DOI Scopus40 WoS34 Europe PMC37
2007 Tarpey, P., Raymond, F., Nguyen, L., Rodriguez, J., Hackett, A., Vandeleur, L., . . . Gecz, J. (2007). Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation. Nature Genetics, 39(9), 1127-1133.
DOI Scopus224 WoS216 Europe PMC208
2007 Karageorgos, L., Brooks, D., Harmatz, P., Ketteridge, D., Pollard, A., Melville, E., . . . Hopwood, J. (2007). Mutational analysis of mucopolysaccharidosis type VI patients undergoing a phase II trial of enzyme replacement therapy. Molecular Genetics and Metabolism, 90(2), 164-170.
DOI Scopus18 WoS17 Europe PMC15
2007 Parkinson-Lawrence, E., Muller, V., Hopwood, J., & Brooks, D. (2007). N-acetylgalactosamine-6-sulfatase protein detection in MPS IVA patient and unaffected control samples. Clinica Chimica Acta, 377(1-2), 88-91.
DOI Scopus6 WoS5 Europe PMC5
2007 Mardones, G., Burgos, P., Brooks, D. A., Parkinson Lawrence, E. J., Mattera, R., & Bonifacino, J. (2007). The trans-golgi network accessory protein p56 promotes long-range movement of GGA/clathrin-containing transport carriers and lysosomal enzyme sorting. Molecular biology of the cell, 18(9), 3486-3501.
DOI Scopus53 WoS50 Europe PMC47
2006 Kakavanos, R., Lehn, P., Callebaut, I., Meikle, P., Parkinson-Lawrence, E., Hopwood, J., & Brooks, D. (2006). Common antigenicity for two glycosidases. FEBS Letters, 580(1), 87-92.
DOI Scopus3 WoS3 Europe PMC2
2006 Parkinson-Lawrence, E., Fuller, M., Hopwood, J., Meikle, P., & Brooks, D. (2006). Immunochemistry of lysosomal storage disorders. Clinical Chemistry, 52(9), 1660-1668.
DOI Scopus26 WoS24 Europe PMC19
2005 Parkinson-Lawrence, E., Turner, C., Hopwood, J., & Brooks, D. (2005). Analysis of normal and mutant iduronate-2-sulphatase conformation. Biochemical Journal, 386(2), 395-400.
DOI Scopus14 WoS12 Europe PMC13
2005 Parkinson-Lawrence, E., Dean, C., Chang, M., Hopwood, J., Meikle, P., & Brooks, D. (2005). Immunochemical analysis of CD107a (LAMP-1). Cellular Immunology, 236(1-2), 161-166.
DOI Scopus23 WoS19 Europe PMC18
2004 Parkinson, E., Muller, V., Hopwood, J., & Brooks, D. (2004). Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients. Molecular Genetics and Metabolism, 81(1), 58-64.
DOI Scopus21 WoS21 Europe PMC18
2002 Bradford, T., Litjens, T., Parkinson, E., Hopwood, J., & Brooks, D. (2002). Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): A Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine 4-sulfatase at multiple points in the vacuolar network. Biochemistry, 41(15), 4962-4971.
DOI Scopus13 WoS11 Europe PMC10
2002 Glaros, E., Turner, C., Parkinson, E., Hopwood, J., & Brooks, D. (2002). Immune response to enzyme replacement therapy: single epitope control of antigen distribution from circulation. Molecular Genetics and Metabolism, 77(1-2), 127-135.
DOI Scopus8 WoS7 Europe PMC6
2001 Brooks, D., Fabrega, S., Hein, L., Parkinson, E., Durand, P., Yogalingam, G., . . . Lehn, P. (2001). Glycosidase active site mutations in human a-L-iduronidase. Glycobiology, 11(9), 741-750.
DOI Scopus24 WoS23 Europe PMC20
2000 Mullock, B., Smith, C., Ihrke, G., Bright, N., Lindsay, M., Parkinson, E., . . . Piper, R. (2000). Syntaxin 7 is localized to late endosome compartments, associates with Vamp 8, and is required for late endosome-lysosome fusion. Molecular Biology of the Cell, 11(9), 3137-3153.
DOI Scopus138 WoS129 Europe PMC126
2000 Parkinson, E. J., Morris, M. B., & Bastiras, S. (2000). Acid denaturation of recombinant porcine growth hormone: Formation and self-association of folding intermediates. BIOCHEMISTRY, 39(40), 12345-12354.
DOI WoS10 Europe PMC7
1996 Hobba, G., Forbes, B., Parkinson, E., Francis, G., & Wallace, J. (1996). The Insulin-like Growth Factor (IGF) Binding Site of Bovine Insulin-like Growth Factor Binding Protein-2 (bIGFBP-2). Journal of Biological Chemistry, 271(48), 30529-30536.
DOI WoS31 Europe PMC23

Year Citation
2022 Orgeig, S., Larcombe, A., Pinniger, G., Tsioutsias, I., & Parkinson-Lawrence, E. (2022). The mucopolysaccharide (MPS) I mouse displays lung and diaphragm dysfunction. In RESPIROLOGY Vol. 27 (pp. 63-64). WILEY.
WoS1
2021 Paget, T., Parkinson-Lawrence, E., Morrison, J., & Orgeig, S. (2021). THE MUCOPOLYSACCHARIDOSIS IIIA (MPS IIIA) MOUSE HAS DECREASED GENE AND PROTEIN EXPRESSION IN SURFACTANT PROTEINS - A, -C AND -D. In RESPIROLOGY Vol. 26 (pp. 140). WILEY.
2021 Paget, T., Larcombe, A., Parkinson-Lawrence, E., & Orgeig, S. (2021). THE MUCOPOLYSACCHARIDOSIS IIIA (MPS IIIA) MOUSE DEMONSTRATES INCREASED COMPLIANCE AND AIRWAY RESISTANCE AND DECREASED TISSUE DAMPING AND ELASTICITY. In RESPIROLOGY Vol. 26 (pp. 182). WILEY.
2020 Valtanen, P. G., Zhang, J., Scammell, A., Parkinson-Lawrence, E., Michael, M., Hussey, D., . . . Hayball, J. (2020). New polyclonal antibody therapeutic to treat esophageal adenocarcinoma and Barrett's esophagus by targeting EPHB4. In ANNALS OF ONCOLOGY Vol. 31 (pp. S167). ELECTR NETWORK: ELSEVIER.
DOI
2019 Paget, T., Parkinson-Lawrence, E., Trim, P., Snel, M., & Orgeig, S. (2019). INCREASED HEPARAN SULPHATE AND DECREASED LIPIDS IN ALVEOLAR SURFACTANT OF THE MUCOPOLYSACCHARIDOSIS (MPS) IIIA MOUSE.. In RESPIROLOGY Vol. 24 (pp. 119). WILEY.
WoS1
2019 Orgeig, S., Larcombe, A., Paget, T., & Parkinson-Lawrence, E. (2019). THE MUCOPOLYSACCHARIDOSIS (MPS) IIIA MOUSE DEMONSTRATES INCREASED AIRWAYS RESISTANCE. In RESPIROLOGY Vol. 24 (pp. 99). WILEY.
2017 Bader, C. A., Sorvina, A., Brooks, R. D., Johnson, I. D., Carter, E., Lay, P., . . . Brooks, D. (2017). LIPID IMAGING IN PROSTATE CANCER.. In MOLECULAR BIOLOGY OF THE CELL Vol. 28 (pp. 2 pages). PA, Philadelphia: AMER SOC CELL BIOLOGY.
2016 Orgeig, S., Syedi, N., Duplock, S., Snel, M., Hemsley, K., & Parkinson-Lawrence, E. (2016). PULMONARY LIPID STORAGE AND LUNG ULTRASTRUCTURE IN THE MUCOPOLYSACCHARIDOSIS IIIA MOUSE. In RESPIROLOGY Vol. 21 (pp. 133). WILEY-BLACKWELL.
2015 Johnson, I. R. D., Parkinson-Lawrence, E. J., Butler, L. M., O'Leary, J. J., & Brooks, D. A. (2015). Altered Endosome Biogenesis in Prostate Cancer Has Prognostic Potential. In JOURNAL OF PATHOLOGY Vol. 237 (pp. S17). Univ Coll D, Dublin, IRELAND: WILEY-BLACKWELL.
2005 Parkinson-Lawrence, E., Muller, V., Hopwood, J., & Brooks, D. (2005). N-ACETYLGALACTOSAMINE 6-SULFATASE PROTEIN DETECTION IN MPS IVA PATIENTS. In JOURNAL OF INHERITED METABOLIC DISEASE Vol. 28 (pp. 190). SPRINGER.
2005 Parkinson-Lawrence, E., Hopwood, J., & Brooks, D. (2005). DIFFERENT LYSOSOMAL STORAGE DISORDERS CAN GENERATE DISTINCT VESICULAR COMPARTMENTS. In JOURNAL OF INHERITED METABOLIC DISEASE Vol. 28 (pp. 151). SPRINGER.

Year Citation
2016 Brooks, D., Parkinson Lawrence, E., Johnson, I., Butler, L., & Weigert, R. (2016). EP3008210, Methods for detecting prostate cancer.
  • Quantification of airway disease in MPS II mice via laboratory X-ray velocimetry, The National MPS Society (USA), 01/04/2024 - 31/03/2025

  • Diagnostic and prognostic biomarker test for prostate cancer, EnVision Sciences Pty Ltd, 01/01/2017 - 30/10/2018

  • Lung function in a mouse model of a paediatric metabolic mouse, The Australian Lung Foundation, 01/05/2016 - 05/03/2018

Date Role Research Topic Program Degree Type Student Load Student Name
2023 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Miss Sammi Ngai

Date Role Research Topic Program Degree Type Student Load Student Name
2017 - 2021 Co-Supervisor Synaptic Morphology, Function, and Regulation in a Paediatric-Onset Neurodegenerative Disorder Doctor of Philosophy Doctorate Full Time Mr Andrew Peter Shoubridge

Connect With Me

External Profiles

Other Links